PHARMACOGENETIC TESTING TO IDENTIFY PRESENCE OF THE HLA-B*57:01 BIOMARKER FOR ABACAVIR TREATMENT
- At: 2019 FIP Congress in AbuDhabi (United Arab Emirates)
- Type: Poster
- By: WIRTH, Francesca (UNIVERSITY OF MALTA, Pharmacy, Malta)
- Co-author(s): Leanne Camilleri: Department of Pharmacy, University of Malta, Msida, Malta
Francesca Wirth: Department of Pharmacy, University of Malta, Msida, Malta
Lilian M Azzopardi: Department of Pharmacy, University of Malta, Msida, Malta
Testing for the HLA-B*57:01 pharmacogenetic (PGx) biomarker is clinically significant to predict risk of hypersensitivity reactions in patients to be treated with abacavir.
A literature search was performed to identify studies describing testing for HLA-B*57:01 with respect to therapy with abacavir. The studies were reviewed and.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.